Open access · US-GOV via ClinicalTrials.gov Clinical trial

Edoxaban Performance in Senior Citizen With Non-valvular Atrial Fibrillation Evaluated Per Frailty

Authors not listed

University of Padova · 2018

Dysbiosis Human Randomized controlled trial

Abstract

Edoxaban, has shown in clinical registration trials a significant reduction of major bleeding compared to warfarin, especially in elderly patients. Efficacy and safety of edoxaban will be assessed in a cohort of very elderly patients (≥80 years of age) with NVAF. A secondary analysis will correlate outcomes with frailty defined according to SHARE-FI (not-frail, pre-frail or frail).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-22 MST

Cite this

APA

Anonymous. (2018). Edoxaban Performance in Senior Citizen With Non-valvular Atrial Fibrillation Evaluated Per Frailty. <em>University of Padova</em>. https://clinicaltrials.gov/study/NCT03524924

Vancouver

Anonymous. Edoxaban Performance in Senior Citizen With Non-valvular Atrial Fibrillation Evaluated Per Frailty. University of Padova. 2018.

BibTeX

@misc{anon2018Edoxab, title = {Edoxaban Performance in Senior Citizen With Non-valvular Atrial Fibrillation Evaluated Per Frailty}, author = {Anonymous}, journal = {University of Padova}, year = {2018}, }